
Agilent Technologies A
$ 135.52
-2.95%
Quarterly report 2025-Q2
added 08-29-2025
Agilent Technologies General and Administrative Expenses 2011-2026 | A
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Agilent Technologies
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.62 B | 1.5 B | 1.46 B | 1.37 B | 1.23 B | 1.25 B | 1.19 B | 2.04 B | 1.88 B | 1.82 B | 1.81 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 2.04 B | 1.19 B | 1.56 B |
Quarterly General and Administrative Expenses Agilent Technologies
| 2025-Q2 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2023-Q4 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 417 M | 410 M | - | 395 M | 396 M | 415 M | 417 M | - | - | 386 M | 407 M | - | 403 M | 420 M | 404 M | 1.11 B | 347 M | 358 M | 355 M | 1.08 B | 366 M | 354 M | 347 M | 1.03 B | 341 M | 341 M | 289 M | 904 M | 308 M | 307 M | 304 M | 932 M | 310 M | 318 M | 310 M | 892 M | 290 M | 292 M | 298 M | 887 M | 285 M | 304 M | 484 M | 1.43 B | 449 M | 497 M | 441 M | 1.35 B | 458 M | 452 M | 446 M | 1.36 B | 449 M | 469 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.43 B | 285 M | 520 M |
General and Administrative Expenses of other stocks in the Diagnostics research industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Akumin
AKU
|
2.08 M | - | -17.87 % | $ 25.9 M | ||
|
Anixa Biosciences
ANIX
|
6.63 M | $ 3.11 | -2.51 % | $ 101 K | ||
|
Centogene N.V.
CNTG
|
46.7 M | - | -6.23 % | $ 30.6 M | ||
|
Accelerate Diagnostics
AXDX
|
39.2 M | - | -61.36 % | $ 2.46 M | ||
|
Brainsway Ltd.
BWAY
|
5.78 M | $ 22.32 | -3.71 % | $ 99.4 M | ||
|
BioNano Genomics
BNGO
|
51.9 M | $ 1.45 | -3.67 % | $ 1.84 M | ||
|
Aspira Women's Health
AWH
|
16.2 M | - | -6.19 % | $ 10.5 M | ||
|
Burning Rock Biotech Limited
BNR
|
490 M | $ 30.5 | -4.72 % | $ 328 M | ||
|
Biocept
BIOC
|
16.1 M | - | -13.05 % | $ 7.29 M | ||
|
Check-Cap Ltd.
CHEK
|
9.46 M | - | - | $ 9.42 M | ||
|
Castle Biosciences
CSTL
|
200 M | $ 40.78 | 1.92 % | $ 1.13 B | ||
|
Co-Diagnostics
CODX
|
14.3 M | - | - | $ 79.8 M | ||
|
DexCom
DXCM
|
1.19 B | $ 70.44 | 1.29 % | $ 27.2 B | ||
|
Oxford Immunotec Global PLC
OXFD
|
22.3 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
24.3 M | - | 0.22 % | $ 16.8 M | ||
|
Guardant Health
GH
|
180 M | $ 113.62 | 1.32 % | $ 13.9 B | ||
|
Global Cord Blood Corporation
CO
|
187 M | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
97.9 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
3.83 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
126 M | - | 0.12 % | $ 80.1 M | ||
|
DermTech
DMTK
|
43.8 M | - | -11.32 % | $ 2.94 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
453 M | - | - | $ 10.7 B | ||
|
Illumina
ILMN
|
1.09 B | $ 147.36 | 4.03 % | $ 23.4 B | ||
|
CareDx, Inc
CDNA
|
118 M | $ 20.08 | 0.35 % | $ 1.08 B | ||
|
Danaher Corporation
DHR
|
7.76 B | $ 234.95 | -0.44 % | $ 172 B | ||
|
Celcuity
CELC
|
9.06 M | $ 105.63 | -1.25 % | $ 4.17 B | ||
|
DarioHealth Corp.
DRIO
|
18.1 M | $ 12.48 | 0.28 % | $ 354 M | ||
|
Enzo Biochem
ENZ
|
21.7 M | - | -8.98 % | $ 14.8 K | ||
|
Fulgent Genetics
FLGT
|
88.1 M | $ 27.65 | -1.53 % | $ 836 M | ||
|
HTG Molecular Diagnostics
HTGM
|
15.8 M | - | -20.0 % | $ 1.06 M | ||
|
Exact Sciences Corporation
EXAS
|
191 M | $ 102.21 | -0.22 % | $ 18.9 B | ||
|
Lantheus Holdings
LNTH
|
194 M | $ 66.02 | 2.75 % | $ 4.57 B | ||
|
Medpace Holdings
MEDP
|
180 M | $ 602.32 | -1.41 % | $ 18.6 B | ||
|
IQVIA Holdings
IQV
|
1.99 B | $ 234.18 | -1.47 % | $ 42.5 B | ||
|
QIAGEN N.V.
QGEN
|
128 M | - | - | $ 10.6 B | ||
|
Heska Corporation
HSKA
|
64.1 M | - | - | $ 1.31 B | ||
|
Neogen Corporation
NEOG
|
218 M | $ 9.28 | 0.27 % | $ 2.01 B | ||
|
National Research Corporation
NRC
|
46.6 M | $ 22.06 | -0.72 % | $ 541 M | ||
|
Charles River Laboratories International
CRL
|
751 M | $ 219.04 | -0.3 % | $ 11.3 B | ||
|
OPKO Health
OPK
|
304 M | $ 1.3 | 1.56 % | $ 902 M | ||
|
Pacific Biosciences of California
PACB
|
170 M | $ 2.36 | 6.79 % | $ 599 M | ||
|
Quest Diagnostics Incorporated
DGX
|
1.77 B | $ 188.87 | -0.33 % | $ 21 B | ||
|
Biodesix
BDSX
|
80.5 M | $ 8.85 | 12.25 % | $ 1.15 B | ||
|
Mettler-Toledo International
MTD
|
936 M | $ 1 409.56 | -3.5 % | $ 29.9 B | ||
|
Laboratory Corporation of America Holdings
LH
|
2.23 B | $ 272.02 | 0.42 % | $ 22.8 B | ||
|
ICON Public Limited Company
ICLR
|
585 M | $ 176.57 | -3.31 % | $ 14.6 B | ||
|
IDEXX Laboratories
IDXX
|
442 M | $ 688.67 | -3.73 % | $ 56.8 B | ||
|
Myriad Genetics
MYGN
|
276 M | $ 5.65 | -4.56 % | $ 512 M | ||
|
ENDRA Life Sciences
NDRA
|
7.06 M | $ 4.67 | -2.3 % | $ 2.51 M |